var data={"title":"Tuberculous lymphadenitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Tuberculous lymphadenitis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/contributors\" class=\"contributor contributor_credentials\">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tuberculous lymphadenitis is among the most frequent presentations of extrapulmonary tuberculosis (TB). Tuberculous lymphadenitis in the cervical region is known as scrofula [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"abstract_t\">1</a>]. This syndrome can also be caused by nontuberculous mycobacteria.</p><p>TB is responsible for up to 43 percent of peripheral lymphadenopathy in the developing world [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/2\" class=\"abstract_t\">2</a>]. In rural India, the prevalence of tuberculous lymphadenitis in children up to 14 years of age is approximately 4.4 cases per 1000 [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/3\" class=\"abstract_t\">3</a>]. In the United States, about 20 percent of patients with TB have extrapulmonary disease, and lymphadenitis is a presenting symptom in about 30 to 40 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/4-6\" class=\"abstract_t\">4-6</a>]. (See <a href=\"topic.htm?path=evaluation-of-peripheral-lymphadenopathy-in-adults\" class=\"medical medical_review\">&quot;Evaluation of peripheral lymphadenopathy in adults&quot;</a>.)</p><p>The human immunodeficiency virus (HIV) epidemic has been associated with an increase in the total incidence of TB and an increased proportion of miliary, disseminated, and extrapulmonary TB cases including lymphadenitis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=epidemiology-of-tuberculosis\" class=\"medical medical_review\">&quot;Epidemiology of tuberculosis&quot;</a> and <a href=\"topic.htm?path=epidemiology-and-pathology-of-miliary-and-extrapulmonary-tuberculosis\" class=\"medical medical_review\">&quot;Epidemiology and pathology of miliary and extrapulmonary tuberculosis&quot;</a>.)</p><p>Issues related to tuberculous lymphadenitis will be reviewed here. Other issues related to tuberculosis are discussed separately. (See related topics.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolated peripheral tuberculous lymphadenopathy is usually due to reactivation of disease at a site seeded hematogenously during primary tuberculosis (TB) infection, perhaps years earlier [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8\" class=\"abstract_t\">8</a>].</p><p>It has been postulated that cervical tuberculous lymphadenitis occurs as a result of TB infection involving the tonsils, adenoids, and Waldeyer's ring, leading to cervical lymphadenopathy [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/2\" class=\"abstract_t\">2</a>]. Abdominal tuberculous lymphadenopathy may occur via ingestion of sputum or milk infected with <em>Mycobacterium tuberculosis</em> or <em>M. bovis </em>[<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=tuberculosis-natural-history-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Tuberculosis: Natural history, microbiology, and pathogenesis&quot;</a> and <a href=\"topic.htm?path=mycobacterium-bovis\" class=\"medical medical_review\">&quot;Mycobacterium bovis&quot;</a>.)</p><p>Though most cases of tuberculous lymphadenitis occur in the setting of reactivation of latent infection, miliary dissemination with prominent lymph node involvement in the setting of primary infection can also occur [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/7,10,11\" class=\"abstract_t\">7,10,11</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The epidemiology of tuberculous lymphadenitis varies between developed and developing countries.</p><p>In developed countries, most cases of tuberculous lymphadenitis occur among adult immigrants from tuberculosis (TB)-endemic countries [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12-14\" class=\"abstract_t\">12-14</a>]. This was illustrated by case series of tuberculous lymphadenitis in France and Germany in which about 70 percent of cases occurred in immigrants; in the German study, two-thirds of patients had immigrated &gt;3 years prior to diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. In the United States, the rate of tuberculous lymphadenitis is higher among Asian Pacific Islanders and in females [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/2,4,15\" class=\"abstract_t\">2,4,15</a>]. Rarely, tuberculous lymphadenitis can also occur in travelers to endemic areas [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Tuberculous lymphadenitis occurs more frequently in women than in men [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Previously, tuberculous lymphadenitis was considered a disease of childhood; however, the peak age of onset in developed countries has shifted from childhood to ages 20 to 40 years [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/18\" class=\"abstract_t\">18</a>]. In contemporary series, the median age has been approximately 40 years in developed countries (range 1 to 88 years) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,14,19\" class=\"abstract_t\">12,14,19</a>].</p><p>In developing countries where TB is endemic, extrapulmonary TB occurs in up to 60 percent of HIV-infected patients with TB and is frequently accompanied by signs of pulmonary involvement [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Most extrapulmonary TB cases (including tuberculous lymphadenitis) occur among patients with HIV at CD4 counts &lt;300 <span class=\"nowrap\">cells/microL</span> (usually below 100 <span class=\"nowrap\">cells/microL)</span> [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/7,23\" class=\"abstract_t\">7,23</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations depend on the site of the lymphadenopathy and the immune status of the patient [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8,10,15,16\" class=\"abstract_t\">8,10,15,16</a>].</p><p>The most common presentation in young adults is isolated chronic nontender lymphadenopathy. Systemic symptoms are not common; fever has been reported in 20 to 50 percent of cases in HIV-uninfected patients and 60 to 80 percent in HIV-infected patients [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"abstract_t\">1</a>]. The mass may be present for up to 12 months before diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16,24\" class=\"abstract_t\">16,24</a>]. Physical examination reveals a firm, discrete mass or matted nodes fixed to surrounding structures; the overlying skin may be indurated [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8\" class=\"abstract_t\">8</a>]. Uncommon findings include fluctuance, draining sinus, or erythema nodosum.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Cervical lymphadenopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cervical lymphadenopathy is the most common manifestation of tuberculous lymphadenitis; in contemporary series, it represents 63 to 77 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,19\" class=\"abstract_t\">12,19</a>].</p><p>Most frequently, a unilateral mass appears in the anterior or posterior cervical triangles; submandibular and supraclavicular lymph node involvement also occurs [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16,20,24,25\" class=\"abstract_t\">16,20,24,25</a>]. Bilateral disease is uncommon (up to 26 percent of cases) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16,26\" class=\"abstract_t\">16,26</a>]. Although most patients have disease at only one site, multiple nodes may be involved at that site [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/15,24\" class=\"abstract_t\">15,24</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Other involved nodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Local complications of tuberculous lymphadenitis are dependent on local anatomical structures:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculous cervical lymphadenitis can be complicated by ulceration, fistula, or abscess formation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mediastinal lymph node involvement usually occurs as a complication of primary tuberculosis (TB). Nodal enlargement can result in compression of the upper airways with bronchial or tracheal stenosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/27-29\" class=\"abstract_t\">27-29</a>]. These complications may be more common in children, who have softer cartilage in their airways, and also more common in patients with HIV [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/27\" class=\"abstract_t\">27</a>]. Tuberculous mediastinal lymphadenopathy can present with dysphagia, esophageal perforation, vocal cord paralysis due to recurrent laryngeal nerve involvement, or pulmonary artery occlusion mimicking pulmonary embolism [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/30-33\" class=\"abstract_t\">30-33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subcarinal node enlargement can cause external compression of both the esophagus (producing dysphagia) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/34\" class=\"abstract_t\">34</a>] and bronchus [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/35\" class=\"abstract_t\">35</a>]. Esophageal perforation and tracheoesophageal fistula have both been reported [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/36\" class=\"abstract_t\">36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculous peritoneal lymphadenopathy most commonly involves lymph nodes in the periportal region, followed by peripancreatic and mesenteric lymph nodes [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/10\" class=\"abstract_t\">10</a>]. Hepatic lymph node involvement can lead to jaundice, portal vein thrombosis, and portal hypertension [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/37\" class=\"abstract_t\">37</a>]. Extrinsic compression of renal arteries due to tuberculous abdominal lymphadenopathy can result in renovascular hypertension [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/38\" class=\"abstract_t\">38</a>]. Enlargement of tuberculous intraabdominal lymph nodes has resulted in external compression of segments of the gastrointestinal tract, such as the duodenum [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p/><p>Other sites of tuberculous lymphadenitis include the axillary, inguinal, and intramammary lymph nodes [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8,10,41\" class=\"abstract_t\">8,10,41</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">HIV coinfection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients with tuberculous lymphadenitis in the setting of HIV infection, there may be a significant mycobacterial load with concomitant systemic findings including fever, sweats, and weight loss [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20\" class=\"abstract_t\">20</a>]. Abnormal chest radiography is frequently observed, and such patients are more likely to have disseminated TB with lymphadenitis at more than one site [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/10,20\" class=\"abstract_t\">10,20</a>]. Patients with mediastinal and hilar node involvement are likely to have active pulmonary TB and may have symptoms including dyspnea and tachypnea [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of isolated peripheral lymphadenopathy is extensive and includes malignancy (eg, Hodgkin lymphoma and non-Hodgkin lymphoma) and other infections (eg, nontuberculous mycobacteria [<em>M. scrofulaceum</em>, <em>M. avium</em> complex, <em>M. kansasii</em>], cat scratch disease, fungal infection, sarcoidosis, and bacterial adenitis).</p><p>Kikuchi disease (idiopathic histiocytic necrotizing lymphadenitis) can mimic tuberculous cervical lymphadenopathy; indistinct margins of necrotic foci demonstrated on computed tomography scan may be an independent predictor of Kikuchi disease [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/43,44\" class=\"abstract_t\">43,44</a>]. The most likely alternative diagnoses depend on the clinical setting including the patient's age, ethnic background, immune status, and presenting clinical features. (See <a href=\"topic.htm?path=kikuchi-disease\" class=\"medical medical_review\">&quot;Kikuchi disease&quot;</a>.)</p><p>It is difficult to differentiate tuberculosis from other causes of lymphadenitis on clinical grounds. One study found no distinguishing clinical features between patients with lymphadenitis due to tuberculous or nontuberculous mycobacteria [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/45\" class=\"abstract_t\">45</a>]. Another report noted the same results regardless of HIV status [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnosis of tuberculous lymphadenitis is established by histopathology examination along with acid-fast bacilli (AFB) smear and culture of lymph node material. Chest imaging should also be obtained.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Material for histopathology evaluation may be obtained by fine needle aspiration or excisional lymph node biopsy.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Fine needle aspiration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fine needle aspiration (FNA) is appropriate for initial evaluation of cervical lymphadenopathy to evaluate for tuberculous lymphadenitis. The yield of FNA appears to be highest in the setting of HIV infection and in regions where the prevalence of tuberculosis (TB) is high [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16,20,46-48\" class=\"abstract_t\">16,20,46-48</a>]. In these circumstances, the burden of organisms is likely to be high. In a series of 1193 patients evaluated for tuberculous lymphadenitis in Hong Kong, for example, FNA had good sensitivity and specificity (77 and 93 percent, respectively) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/49\" class=\"abstract_t\">49</a>].</p><p>FNA is a relatively safe and inexpensive procedure, with few complications when a 21 to 23 gauge needle is used [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16\" class=\"abstract_t\">16</a>]. Specimens should be submitted for microscopy, culture, cytology, and polymerase chain reaction testing (where available).</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Excisional biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Excisional lymph node biopsy for histopathologic and microbiological evaluations has the highest diagnostic yield and should be pursued in cases where fine needle aspiration is not diagnostic [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/25,49\" class=\"abstract_t\">25,49</a>]. In a series of 47 patients evaluated for tuberculous lymphadenitis, for example, the diagnosis of TB was established by excisional biopsy in all cases; FNA was definitive in only 62 percent [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/25\" class=\"abstract_t\">25</a>]. In studies from developed countries, <em>M. tuberculosis</em> is typically cultured from excisional biopsies in 70 to 90 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"abstract_t\">1</a>]. Excisional biopsy is preferred over incisional biopsy; the latter may be associated with sinus tract formation. For mediastinal lymph node biopsy, mediastinoscopy may be required.</p><p>Specimens should be submitted for histology, acid-fast stain, culture, and nucleic acid amplification testing. (See <a href=\"#H15619792\" class=\"local\">'Culture and nucleic acid amplification testing'</a> below.)</p><p>The finding of caseating granulomas on histopathology is highly suggestive of TB although is not diagnostic since other diseases can also have similar histology [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H15619792\"><span class=\"h2\">Culture and nucleic acid amplification testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nucleic acid amplification (NAA) testing can facilitate the diagnosis of TB in lymph node tissues (including aspirates) for which histology findings are not specific and acid-fast organisms are not seen [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/50-53\" class=\"abstract_t\">50-53</a>]. In a systematic review and meta-analysis including 18 studies, the sensitivity and specificity for the Xpert <span class=\"nowrap\">MTB/RIF</span> assay (compared with culture) in lymph nodes were 83 and 94 percent, respectively [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/52\" class=\"abstract_t\">52</a>].</p><p>No commercial NAA platform is approved by the US Food and Drug Administration for diagnosis of nonrespiratory tract TB. However, individual laboratories may validate and perform NAA testing on nonrespiratory samples; reporting language should indicate that this is a non-approved (&quot;off-label&quot;) use of the test.</p><p>Serial NAA testing cannot be used to monitor response to therapy, since it reflects presence of <em>M. tuberculosis</em>&ndash;complex nucleic acid but not viability.</p><p>Culture for mycobacteria remains the gold standard for diagnosis of tuberculosis. Culture permits drug susceptibility testing and must be performed to inform treatment decisions, even if NAA testing is positive.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Imaging</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Chest imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In nonendemic countries, most patients with tuberculous lymphadenitis have no evidence of active pulmonary TB on chest radiograph (90 to 100 percent) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,17\" class=\"abstract_t\">12,17</a>]. However, pleural thickening and apical fibrosis suggestive of previous TB may be observed [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8,20\" class=\"abstract_t\">8,20</a>]. In TB-endemic countries, pulmonary involvement is observed in 20 to 40 percent of patients with tuberculous lymphadenitis. Chest radiograph abnormalities have been described more frequently among patients with HIV infection in some series. One report of 10 HIV-infected patients described abnormal radiography on presentation with tuberculous lymphadenitis in 90 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Chest imaging suggestive of active pulmonary TB should prompt further evaluation, as outlined separately. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults#H340212714\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;, section on 'Radiographic imaging'</a> and <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Neck imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neck imaging modalities include ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ultrasonography &ndash; In a study comparing lymph node metastases with tuberculous lymphadenitis, the latter was associated with a higher incidence of abnormal surrounding soft tissue, cystic necrosis, matting, posterior enhancement (when structures posterior to the node were more echogenic than neighboring structures), and a heterogeneous rather than a homogenous pattern [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/54\" class=\"abstract_t\">54</a>]. A subsequent study using endobronchial ultrasound demonstrated that presence of necrosis and absence of the clustered formation were independent predictors of tuberculous lymph nodes [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/55\" class=\"abstract_t\">55</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Computed tomography &ndash; CT and positron emission tomography (PET-CT) can be useful to identify involved lymph nodes for biopsy or to monitor responses to treatment (<a href=\"image.htm?imageKey=ID%2F67296\" class=\"graphic graphic_diagnosticimage graphicRef67296 \">image 1</a>). However, radiographic findings of lymphadenopathy are not specific for TB, especially when trying to distinguish tuberculous lymphadenitis from lymphoma or other malignancy [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/56-58\" class=\"abstract_t\">56-58</a>]. In one Chinese series including 26 patients with tuberculous lymphadenitis and 43 patients with lymphoma, lower paraaortic node involvement was more common in lymphoma; TB more often involved upper paraaortic, lesser omental, mesenteric, and anterior pararenal lymph nodes [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/9\" class=\"abstract_t\">9</a>]. Peripheral enhancement (often with a multilocular appearance) was also a feature of tuberculous lymphadenopathy; homogeneous attenuation was more common in the setting of lymphomatous adenopathy. In another study comparing CT findings in Kikuchi disease and tuberculous lymphadenitis, patients with Kikuchi disease had involvement of multiple nodal levels, minimal or no nodal necrosis, marked perinodal infiltration, and no evidence of upper lung pathology or mediastinal lymphadenopathy [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/59\" class=\"abstract_t\">59</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Magnetic resonance imaging &ndash; In a report of MRI evaluation among nine Chinese patients with tuberculous lymphadenitis, three patterns of disease were noted: discrete nodes, matted nodes, and confluent masses [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/60\" class=\"abstract_t\">60</a>]. Necrotic foci, when present, were more frequently peripheral rather than central.</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Other diagnostic tools</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnosis of tuberculous lymphadenitis is established by histopathology examination and AFB smear and culture of lymph node material as discussed above. Additional diagnostic tools that may be useful in the setting of suspected tuberculous lymphadenitis are outlined below. Further discussion of issues related to diagnosis of TB is presented separately. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sputum smear and culture &ndash; Positive sputum cultures are uncommon (0 to 14 percent) in the setting of tuberculous lymphadenitis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,16,61\" class=\"abstract_t\">12,16,61</a>]. Chest radiography findings consistent with active pulmonary TB should prompt sputum cultures; if positive, evaluation for miliary TB should be pursued. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of miliary tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchoscopy &ndash; In the setting of isolated intrathoracic lymphadenopathy, bronchoscopy may be useful to establish a diagnosis of TB if sputum studies are negative [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/62,63\" class=\"abstract_t\">62,63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) &ndash; This modality may be useful in the setting of isolated intrathoracic lymphadenopathy [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/64-66\" class=\"abstract_t\">64-66</a>]. In one report of 24 patients with isolated intrathoracic lymphadenopathy and a high clinical suspicion for tuberculosis, material obtained by EBUS-TBNA confirmed the diagnosis in 79 percent of cases (sensitivity and specificity 95 and 100 percent, respectively) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ultrasound-guided core biopsy is an uncommonly used tool with reported utility in the tissue diagnosis of tuberculosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/67\" class=\"abstract_t\">67</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood culture &ndash; Blood cultures for <em>M. tuberculosis</em> are rarely positive but may be positive in disseminated TB, especially in patients with HIV and other forms of immunosuppression [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">Tuberculin skin test</a> &ndash; The tuberculin skin test (TST) is positive in the majority (74 to 100 percent) of patients with tuberculous lymphadenitis (in the absence of HIV infection), although positive TST is not sufficient to establish the diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8,12,14,16,17,20\" class=\"abstract_t\">8,12,14,16,17,20</a>]. A negative TST is not helpful in excluding the diagnosis, especially in immunosuppressed individuals [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Interferon-gamma release assays (IGRAs) &ndash; The IGRA's high sensitivity and specificity for diagnosis of TB lymphadenitis but positive test result are not sufficient to establish a diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/69,70\" class=\"abstract_t\">69,70</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIV testing &ndash; Patients with suspected or proven TB should undergo HIV testing [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/42\" class=\"abstract_t\">42</a>]. (See <a href=\"topic.htm?path=screening-and-diagnostic-testing-for-hiv-infection\" class=\"medical medical_review\">&quot;Screening and diagnostic testing for HIV infection&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of tuberculous lymphadenitis consists of multidrug antimycobacterial therapy. In some circumstances, excisional biopsy in theory may be sufficient for treatment of immunocompetent patients with localized disease, though in general all patients should also receive antimycobacterial therapy.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Choice of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The American Thoracic Society (ATS), Centers for Disease Control (CDC), and the Infectious Diseases Society of America (IDSA) have published recommendations for the treatment of tuberculosis (TB) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/71\" class=\"abstract_t\">71</a>]. In general, treatment for adults with drug-susceptible tuberculous lymphadenitis consists of two months of rifampicin, <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> (given daily) followed by four months of rifampicin and isoniazid (given either daily or three times weekly) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/72\" class=\"abstract_t\">72</a>]. Dosing, monitoring, and further details related to antimycobacterial regimens for TB are presented separately as are issues related to patients with HIV infection. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p>The recommended duration of therapy for HIV-uninfected adults is six months [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/71,73,74\" class=\"abstract_t\">71,73,74</a>]. In a randomized trial comparing a six-month regimen (four drugs for four months followed by two drugs for two months) with a nine-month regimen (four drugs for four months followed by two drugs for five months), there was no difference in treatment failure or remission at five years between the two regimens [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Alternative regimens for drug-susceptible <em>M. tuberculosis</em> have been evaluated among 277 patients with tuberculous lymphadenitis in India (90 percent of patients had fully susceptible <em>M. tuberculosis</em>), including two months of rifampicin, <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> (two times weekly) followed by four months of rifampicin and isoniazid (two times weekly), and six-month regimen of daily rifampicin and isoniazid [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/72\" class=\"abstract_t\">72</a>]. The latter two-drug regimen is not recommended even though these regimens were comparable in the trial.</p><p>The optimal duration of therapy in children is uncertain [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/75\" class=\"abstract_t\">75</a>]. The relapse rate in children after six months of therapy is not well established; nine months of therapy may be appropriate pending further study.</p><p>Longer duration of therapy also may be appropriate for patients with HIV infection with evidence of suboptimal response, those who cannot tolerate first-line medications, or patients who have infection due to resistant organisms [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/71\" class=\"abstract_t\">71</a>]. In such situations, selection and duration of therapy should be individualized in consultation with a clinician with expertise in tuberculosis. Further consultation for diagnosis and management may be obtained through the CDC's <a href=\"http://www.cdc.gov/tb/education/rtmc/default.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsQulwAmMHHLqr1ByRDOU5YCMiO8p5vd20DY4x0jDgNe8qEu38frBnt1uSQ6Z63IY2Q==&amp;TOPIC_ID=8001\" target=\"_blank\" class=\"external\">Regional Training and Medical Consultation Centers</a>. Treatment of drug-resistant tuberculosis is discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tuberculous lymphadenitis is characteristically slow to respond to effective treatment, and nodes may enlarge during treatment or after cessation of treatment.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Paradoxical reaction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimycobacterial therapy may prompt a paradoxical reaction or increase in lymph node size <span class=\"nowrap\">and/or</span> enlargement of additional lymph nodes in up to 20 percent of patients during or after cessation of treatment [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1,12,61\" class=\"abstract_t\">1,12,61</a>]. Most paradoxical reactions occur between three weeks and four months after initiation of treatment [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"abstract_t\">1</a>]. Cultures are usually negative, and such reactions do not usually indicate treatment failure.</p><p>Paradoxical reactions have been attributed to an immune response to dying <em>M. tuberculosis</em> organisms [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/76,77\" class=\"abstract_t\">76,77</a>]. Clinical manifestations may include lymph node enlargement (12 percent), fluctuance (11 percent), overlying erythema, <span class=\"nowrap\">and/or</span> spontaneous discharge (7 percent) [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/61,78\" class=\"abstract_t\">61,78</a>]. Constitutional symptoms are uncommon [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/61\" class=\"abstract_t\">61</a>]. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p>In HIV-uninfected patients, such paradoxical reactions occur in up to 23 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12,61,76,79\" class=\"abstract_t\">12,61,76,79</a>]. Predictors include male gender, presence of local erythema at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/76\" class=\"abstract_t\">76</a>], presence of a positive <em>M. tuberculosis</em> culture, and peripheral lymph node disease [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/80\" class=\"abstract_t\">80</a>].</p><p>In HIV-infected patients, paradoxical reactions are more common in some but not all reports [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/81,82\" class=\"abstract_t\">81,82</a>]. It may be more temporally associated with the initiation of antiretroviral therapy (ART) than antituberculosis therapy [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/81\" class=\"abstract_t\">81</a>]. There appears to be no association between baseline CD4 counts or CD4 response to ART [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/83\" class=\"abstract_t\">83</a>].</p><p>The differential diagnosis includes treatment failure due to resistance or noncompliance, another infection, or an alternative diagnosis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/83\" class=\"abstract_t\">83</a>].</p><p>There are no consensus guidelines for management of paradoxical reaction, and the approach should be based on whether the patient is experiencing significant discomfort. Options include observation, aspiration, surgical excision, or a trial of nonsteroidal anti-inflammatory agents or corticosteroids. <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> has also been used in this setting [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Fine needle aspiration (FNA) for acid-fast bacillus microscopy and culture may be pursued to distinguish between a paradoxical reaction and treatment failure.</p><p>In one study of 235 HIV-uninfected patients, spontaneous resolution of paradoxical lymph node enlargement occurred in 56 percent of cases [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/76\" class=\"abstract_t\">76</a>]. In a second study including both HIV-infected and -uninfected patients, spontaneous resolution occurred in all patients in mean period of 2.5 months; some patients underwent aspiration or excision [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Relapse rates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Relapse rates of up to 3.5 percent have been reported in patients treated for tuberculous lymphadenitis [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/74\" class=\"abstract_t\">74</a>]. A minority (7 to 11 percent) of patients have residual lymph nodes present at the end of the treatment course [<a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/74,78,85\" class=\"abstract_t\">74,78,85</a>].</p><p class=\"headingAnchor\" id=\"H2758075376\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of tuberculosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculous lymphadenitis is among the most frequent presentations of extrapulmonary tuberculosis (TB). Tuberculous lymphadenitis in the cervical region is known as scrofula. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Isolated peripheral tuberculous lymphadenopathy is usually due to reactivation of disease at a site seeded hematogenously during primary TB infection, perhaps years earlier. Miliary dissemination with prominent lymph node involvement in the setting of primary infection can also occur. (See <a href=\"#H2\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Previously, tuberculous lymphadenitis was considered a disease of childhood; however, in reports from developed countries, the peak age of onset has shifted from childhood to ages 20 to 40 years. In developed countries, most cases of tuberculous lymphadenitis occur among immigrants from TB-endemic countries. In regions where TB is endemic, extrapulmonary TB occurs in approximately 60 percent of HIV-infected patients with TB and is frequently accompanied by signs of pulmonary involvement. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations depend on the site of the lymphadenopathy and the immune status of the patient. The most common presentation is isolated chronic nontender lymphadenopathy in a young adult without systemic symptoms other than fever, most commonly in the cervical region. Physical examination reveals a firm, discrete mass or matted nodes fixed to surrounding structures; the overlying skin may be indurated. (See <a href=\"#H4\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with tuberculous lymphadenitis in the setting of HIV infection, there may be a significant mycobacterial load with concomitant systemic findings including fever, sweats, and weight loss. Abnormal chest radiography is frequently observed, and such patients are more likely to have disseminated TB with lymphadenitis at more than one site. (See <a href=\"#H7\" class=\"local\">'HIV coinfection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis of tuberculous lymphadenitis is established by histopathology examination along with acid-fast bacilli (AFB) smear and culture of lymph node material. Fine needle aspiration (FNA) is appropriate for initial evaluation of cervical lymphadenopathy to evaluate for tuberculous lymphadenitis. The yield of FNA appears to be highest in the setting of HIV infection and in regions where the prevalence of TB is high. Specimens should be submitted for microscopy, culture, cytology, and nucleic acid testing (where available). Excisional lymph node biopsy for histopathologic and microbiological evaluation has the highest diagnostic yield and should be pursued in cases where fine needle aspiration is not diagnostic or for persistent disease despite appropriate therapy. (See <a href=\"#H10\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest imaging should be pursued in the setting of suspected tuberculous lymphadenitis. Most patients from nonendemic countries with suspected tuberculous lymphadenitis have no evidence of active pulmonary TB on chest radiograph, while patients from endemic countries have chest radiograph abnormalities in 20 to 40 percent of cases. Abnormalities have been described more frequently among patients with HIV infection in some series. (See <a href=\"#H13\" class=\"local\">'Imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment for HIV-uninfected adults with tuberculous lymphadenitis, we suggest the following regimen: two months of rifampicin, <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> (given daily) followed by four months of rifampicin and isoniazid (given either daily or three times weekly) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The preferred duration of therapy for adults is six months. The optimal duration of therapy in children is uncertain, as the relapse rate after six months of therapy is not well established; nine months of therapy may be appropriate pending further study. (See <a href=\"#H17\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paradoxical upgrading reactions may occur in as many as 20 percent of patients, are usually culture negative, and do not usually represent treatment failure. (See <a href=\"#H20\" class=\"local\">'Paradoxical reaction'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/1\" class=\"nounderline abstract_t\">Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis 2011; 53:555.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/2\" class=\"nounderline abstract_t\">Dandapat MC, Mishra BM, Dash SP, Kar PK. Peripheral lymph node tuberculosis: a review of 80 cases. Br J Surg 1990; 77:911.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/3\" class=\"nounderline abstract_t\">Narang P, Narang R, Narang R, et al. Prevalence of tuberculous lymphadenitis in children in Wardha district, Maharashtra State, India. Int J Tuberc Lung Dis 2005; 9:188.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/4\" class=\"nounderline abstract_t\">Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141:347.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/5\" class=\"nounderline abstract_t\">Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009; 49:1350.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Tuberculosis (TB): Reported Tuberculosis in the United States, 2013. http://www.cdc.gov/tb/statistics/reports/2013/default.htm (Accessed on July 29, 2015).</li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/7\" class=\"nounderline abstract_t\">Hill AR, Premkumar S, Brustein S, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991; 144:1164.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/8\" class=\"nounderline abstract_t\">Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore) 1984; 63:25.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/9\" class=\"nounderline abstract_t\">Yang ZG, Min PQ, Sone S, et al. Tuberculosis versus lymphomas in the abdominal lymph nodes: evaluation with contrast-enhanced CT. AJR Am J Roentgenol 1999; 172:619.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/10\" class=\"nounderline abstract_t\">Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70:384.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/11\" class=\"nounderline abstract_t\">Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/12\" class=\"nounderline abstract_t\">Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest 2002; 121:1177.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/13\" class=\"nounderline abstract_t\">Fain O, Lortholary O, Djouab M, et al. Lymph node tuberculosis in the suburbs of Paris: 59 cases in adults not infected by the human immunodeficiency virus. Int J Tuberc Lung Dis 1999; 3:162.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/14\" class=\"nounderline abstract_t\">Wark P, Goldberg H, Ferson M, et al. Mycobacterial lymphadenitis in eastern Sydney. Aust N Z J Med 1998; 28:453.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/15\" class=\"nounderline abstract_t\">Castro DJ, Hoover L, Castro DJ, Zuckerbraun L. Cervical mycobacterial lymphadenitis. Medical vs surgical management. Arch Otolaryngol 1985; 111:816.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/16\" class=\"nounderline abstract_t\">Artenstein AW, Kim JH, Williams WJ, Chung RC. Isolated peripheral tuberculous lymphadenitis in adults: current clinical and diagnostic issues. Clin Infect Dis 1995; 20:876.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/17\" class=\"nounderline abstract_t\">Thompson MM, Underwood MJ, Sayers RD, et al. Peripheral tuberculous lymphadenopathy: a review of 67 cases. Br J Surg 1992; 79:763.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/18\" class=\"nounderline abstract_t\">Perlman DC, D'Amico R, Salomon N. Mycobacterial Infections of the Head and Neck. Curr Infect Dis Rep 2001; 3:233.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/19\" class=\"nounderline abstract_t\">Mert A, Tabak F, Ozaras R, et al. Tuberculous lymphadenopathy in adults: a review of 35 cases. Acta Chir Belg 2002; 102:118.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/20\" class=\"nounderline abstract_t\">Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis 1992; 15:601.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/21\" class=\"nounderline abstract_t\">Atomiya AN, Uip DE, Leite OH. Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient. Braz J Infect Dis 2002; 6:29.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/22\" class=\"nounderline abstract_t\">Lee MP, Chan JW, Ng KK, Li PC. Clinical manifestations of tuberculosis in HIV-infected patients. Respirology 2000; 5:423.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/23\" class=\"nounderline abstract_t\">Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/24\" class=\"nounderline abstract_t\">Shikhani AH, Hadi UM, Mufarrij AA, Zaytoun GM. Mycobacterial cervical lymphadenitis. Ear Nose Throat J 1989; 68:660, 662.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/25\" class=\"nounderline abstract_t\">Lee KC, Tami TA, Lalwani AK, Schecter G. Contemporary management of cervical tuberculosis. Laryngoscope 1992; 102:60.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/26\" class=\"nounderline abstract_t\">Agarwal AK, Sethi A, Sethi D, et al. Tubercular cervical adenitis: clinicopathologic analysis of 180 cases. J Otolaryngol Head Neck Surg 2009; 38:521.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/27\" class=\"nounderline abstract_t\">Freixinet J, Varela A, Lopez Rivero L, et al. Surgical treatment of childhood mediastinal tuberculous lymphadenitis. Ann Thorac Surg 1995; 59:644.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/28\" class=\"nounderline abstract_t\">Awad WI, Graves TD, White VC, Wong K. Airway obstruction complicating mediastinal tuberculosis: a life-threatening presentation. Ann Thorac Surg 2002; 74:261.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/29\" class=\"nounderline abstract_t\">Papagiannopoulos KA, Linegar AG, Harris DG, Rossouw GJ. Surgical management of airway obstruction in primary tuberculosis in children. Ann Thorac Surg 1999; 68:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/30\" class=\"nounderline abstract_t\">Popli MB. Dysphagia: a rare presentation of tuberculous mediastinal lymphadenitis. Australas Radiol 1998; 42:143.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/31\" class=\"nounderline abstract_t\">Ohtake M, Saito H, Okuno M, et al. Esophagomediastinal fistula as a complication of tuberculous mediastinal lymphadenitis. Intern Med 1996; 35:984.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/32\" class=\"nounderline abstract_t\">Rafay MA. Tuberculous lymphadenopathy of superior mediastinum causing vocal cord paralysis. Ann Thorac Surg 2000; 70:2142.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/33\" class=\"nounderline abstract_t\">Drake WM, Elkin SL, al-Kutoubi A, et al. Pulmonary artery occlusion by tuberculous mediastinal lymphadenopathy. Thorax 1997; 52:301.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/34\" class=\"nounderline abstract_t\">Rathinam S, Kanagavel M, Tiruvadanan BS, et al. Dysphagia due to tuberculosis. Eur J Cardiothorac Surg 2006; 30:833.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/35\" class=\"nounderline abstract_t\">Lucas S, Andronikou S, Goussard P, Gie R. CT features of lymphobronchial tuberculosis in children, including complications and associated abnormalities. Pediatr Radiol 2012; 42:923.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/36\" class=\"nounderline abstract_t\">Okten I, Cangir AK, Ozdemir N, et al. Management of esophageal perforation. Surg Today 2001; 31:36.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/37\" class=\"nounderline abstract_t\">Caroli-Bosc FX, Conio M, Maes B, et al. Abdominal tuberculosis involving hepatic hilar lymph nodes. A cause of portal vein thrombosis and portal hypertension. J Clin Gastroenterol 1997; 25:541.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/38\" class=\"nounderline abstract_t\">Puri S, Khurana SB, Malhotra S. Tuberculous abdominal lymphadenopathy causing reversible renovascular hypertension. J Assoc Physicians India 2000; 48:530.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/39\" class=\"nounderline abstract_t\">Sakhri J, Youssef S, Beltaifa D, et al. [Tuberculosis abdominal lymphadenitis revealed by a duodenal stenosis]. Bull Soc Pathol Exot 2004; 97:247.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/40\" class=\"nounderline abstract_t\">Al-Hilou H, Carroll N, Jah A, et al. A rare cause of duodenal stricture. BMJ Case Rep 2011; 2011.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/41\" class=\"nounderline abstract_t\">Yilmaz F, Yagmur Y, Uzunlar AK. Tuberculosis in an intramammary lymph node. Eur J Surg 2000; 166:267.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/42\" class=\"nounderline abstract_t\">Centers for Disease Control (CDC). Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1989; 38:236.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/43\" class=\"nounderline abstract_t\">Kamath MP, Bhojwani K, Naik R, et al. Tuberculosis mimicking Kikuchi's disease. Ear Nose Throat J 2006; 85:126.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/44\" class=\"nounderline abstract_t\">Lee S, Yoo JH, Lee SW. Kikuchi disease: differentiation from tuberculous lymphadenitis based on patterns of nodal necrosis on CT. AJNR Am J Neuroradiol 2012; 33:135.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/45\" class=\"nounderline abstract_t\">Chao SS, Loh KS, Tan KK, Chong SM. Tuberculous and nontuberculous cervical lymphadenitis: a clinical review. Otolaryngol Head Neck Surg 2002; 126:176.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/46\" class=\"nounderline abstract_t\">Pithie AD, Chicksen B. Fine-needle extrathoracic lymph-node aspiration in HIV-associated sputum-negative tuberculosis. Lancet 1992; 340:1504.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/47\" class=\"nounderline abstract_t\">Ellison E, Lapuerta P, Martin SE. Fine needle aspiration diagnosis of mycobacterial lymphadenitis. Sensitivity and predictive value in the United States. Acta Cytol 1999; 43:153.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/48\" class=\"nounderline abstract_t\">Jha BC, Dass A, Nagarkar NM, et al. Cervical tuberculous lymphadenopathy: changing clinical pattern and concepts in management. Postgrad Med J 2001; 77:185.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/49\" class=\"nounderline abstract_t\">Lau SK, Wei WI, Hsu C, Engzell UC. Efficacy of fine needle aspiration cytology in the diagnosis of tuberculous cervical lymphadenopathy. J Laryngol Otol 1990; 104:24.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/50\" class=\"nounderline abstract_t\">Singh KK, Muralidhar M, Kumar A, et al. Comparison of in house polymerase chain reaction with conventional techniques for the detection of Mycobacterium tuberculosis DNA in granulomatous lymphadenopathy. J Clin Pathol 2000; 53:355.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/51\" class=\"nounderline abstract_t\">Tarng DC, Su WJ, Huang TP. PCR diagnosis on formalin-fixed, paraffin-embedded tissues with acid-fast stain and culture negativity in chronic dialysis patients of cervico-mediastinal tuberculous lymphadenitis. Nephrol Dial Transplant 1998; 13:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/52\" class=\"nounderline abstract_t\">Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014; 44:435.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/53\" class=\"nounderline abstract_t\">Zewdie O, Abebe T, Mihret A, et al. Concentration of fine needle aspirates similar to molecular method improves sensitivity of the diagnosis of tuberculous lymphadenitis in Addis Ababa, Ethiopia. BMC Infect Dis 2017; 17:77.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/54\" class=\"nounderline abstract_t\">Ying M, Ahuja AT, Evans R, et al. Cervical lymphadenopathy: sonographic differentiation between tuberculous nodes and nodal metastases from non-head and neck carcinomas. J Clin Ultrasound 1998; 26:383.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/55\" class=\"nounderline abstract_t\">Wang L, Wu W, Teng J, et al. Sonographic Features of Endobronchial Ultrasound in Differentiation of Benign Lymph Nodes. Ultrasound Med Biol 2016; 42:2785.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/56\" class=\"nounderline abstract_t\">Ito K, Morooka M, Kubota K. 18F-FDG PET/CT findings of pharyngeal tuberculosis. Ann Nucl Med 2010; 24:493.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/57\" class=\"nounderline abstract_t\">Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of &sup1;&#8312;F-FDG PET and PET/CT. Curr Opin Pulm Med 2014; 20:287.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/58\" class=\"nounderline abstract_t\">Sathekge M, Maes A, D'Asseler Y, et al. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 2012; 39:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/59\" class=\"nounderline abstract_t\">Baek HJ, Lee JH, Lim HK, et al. Diagnostic accuracy of the clinical and CT findings for differentiating Kikuchi's disease and tuberculous lymphadenitis presenting with cervical lymphadenopathy. Jpn J Radiol 2014; 32:637.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/60\" class=\"nounderline abstract_t\">King AD, Ahuja AT, Metreweli C. MRI of tuberculous cervical lymphadenopathy. J Comput Assist Tomogr 1999; 23:244.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/61\" class=\"nounderline abstract_t\">Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore) 2005; 84:350.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/62\" class=\"nounderline abstract_t\">Raffy O, Sleiman C, Roue C. Fibreoptic bronchoscopy for diagnosis of isolated tuberculous mediastinal lymphadenopathy. Thorax 1996; 51:967.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/63\" class=\"nounderline abstract_t\">Baran R, Tor M, Tahao&#287;lu K, et al. Intrathoracic tuberculous lymphadenopathy: clinical and bronchoscopic features in 17 adults without parenchymal lesions. Thorax 1996; 51:87.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/64\" class=\"nounderline abstract_t\">Hassan T, McLaughlin AM, O'Connell F, et al. EBUS-TBNA performs well in the diagnosis of isolated thoracic tuberculous lymphadenopathy. Am J Respir Crit Care Med 2011; 183:136.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/65\" class=\"nounderline abstract_t\">Navani N, Molyneaux PL, Breen RA, et al. Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax 2011; 66:889.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/66\" class=\"nounderline abstract_t\">Boonsarngsuk V, Saengsri S, Santanirand P. Endobronchial ultrasound-guided transbronchial needle aspiration rinse fluid polymerase chain reaction in the diagnosis of intrathoracic tuberculous lymphadenitis. Infect Dis (Lond) 2017; 49:193.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/67\" class=\"nounderline abstract_t\">Altuwairgi O, Baharoon S, Alkabab Y, et al. Ultrasound-guided core biopsy in the diagnostic work-up of tuberculous lymphadenitis in Saudi Arabia, refining the diagnostic approach. Case series and review of literature. J Infect Public Health 2014; 7:371.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/68\" class=\"nounderline abstract_t\">Gopinath K, Kumar S, Singh S. Prevalence of mycobacteremia in Indian HIV-infected patients detected by the MB/BacT automated culture system. Eur J Clin Microbiol Infect Dis 2008; 27:423.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/69\" class=\"nounderline abstract_t\">Song KH, Jeon JH, Park WB, et al. Usefulness of the whole-blood interferon-gamma release assay for diagnosis of extrapulmonary tuberculosis. Diagn Microbiol Infect Dis 2009; 63:182.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/70\" class=\"nounderline abstract_t\">Kim KH, Kim RB, Woo SH. The efficacy of the interferon-&gamma; release assay for diagnosing cervical tuberculous lymphadenitis: A prospective controlled study. Laryngoscope 2016; 126:378.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/71\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/72\" class=\"nounderline abstract_t\">Jawahar MS, Rajaram K, Sivasubramanian S, et al. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. Trop Med Int Health 2005; 10:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/73\" class=\"nounderline abstract_t\">Yuen AP, Wong SH, Tam CM, et al. Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngol Head Neck Surg 1997; 116:189.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/74\" class=\"nounderline abstract_t\">van Loenhout-Rooyackers JH, Laheij RJ, Richter C, Verbeek AL. Shortening the duration of treatment for cervical tuberculous lymphadenitis. Eur Respir J 2000; 15:192.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/75\" class=\"nounderline abstract_t\">McMaster P, Isaacs D. Critical review of evidence for short course therapy for tuberculous adenitis in children. Pediatr Infect Dis J 2000; 19:401.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/76\" class=\"nounderline abstract_t\">Cho OH, Park KH, Kim T, et al. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect 2009; 59:56.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/77\" class=\"nounderline abstract_t\">Yu SN, Cho OH, Park KH, et al. Late paradoxical lymph node enlargement during and after anti-tuberculosis treatment in non-HIV-infected patients. Int J Tuberc Lung Dis 2015; 19:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/78\" class=\"nounderline abstract_t\">Campbell IA. The treatment of superficial tuberculous lymphadenitis. Tubercle 1990; 71:1.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/79\" class=\"nounderline abstract_t\">Carvalho AC, De Iaco G, Saleri N, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 2006; 42:893.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/80\" class=\"nounderline abstract_t\">Brown CS, Smith CJ, Breen RA, et al. Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study. BMC Infect Dis 2016; 16:479.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/81\" class=\"nounderline abstract_t\">Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/82\" class=\"nounderline abstract_t\">Wendel KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120:193.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/83\" class=\"nounderline abstract_t\">Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/84\" class=\"nounderline abstract_t\">Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47:e83.</a></li><li><a href=\"https://www.uptodate.com/contents/tuberculous-lymphadenitis/abstract/85\" class=\"nounderline abstract_t\">Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee. Br Med J (Clin Res Ed) 1985; 290:1106.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8001 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Cervical lymphadenopathy</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Other involved nodes</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">HIV coinfection</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIAGNOSIS</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Histopathology</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Fine needle aspiration</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Excisional biopsy</a></li></ul></li><li><a href=\"#H15619792\" id=\"outline-link-H15619792\">Culture and nucleic acid amplification testing</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Imaging</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Chest imaging</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Neck imaging</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Other diagnostic tools</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">TREATMENT</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Choice of therapy</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Response to therapy</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">- Paradoxical reaction</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Relapse rates</a></li></ul></li></ul></li><li><a href=\"#H2758075376\" id=\"outline-link-H2758075376\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8001|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/67296\" class=\"graphic graphic_diagnosticimage\">- Computed tomography - Tuberculous lymphadenopathy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Diagnosis of pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathology-of-miliary-and-extrapulmonary-tuberculosis\" class=\"medical medical_review\">Epidemiology and pathology of miliary and extrapulmonary tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-tuberculosis\" class=\"medical medical_review\">Epidemiology of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-peripheral-lymphadenopathy-in-adults\" class=\"medical medical_review\">Evaluation of peripheral lymphadenopathy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=kikuchi-disease\" class=\"medical medical_review\">Kikuchi disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycobacterium-bovis\" class=\"medical medical_review\">Mycobacterium bovis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-and-diagnostic-testing-for-hiv-infection\" class=\"medical medical_review\">Screening and diagnostic testing for HIV infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Treatment of drug-resistant pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-natural-history-microbiology-and-pathogenesis\" class=\"medical medical_review\">Tuberculosis: Natural history, microbiology, and pathogenesis</a></li></ul></div></div>","javascript":null}